IBDEI1YD ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33147,1,4,0)
 ;;=4^I71.4
 ;;^UTILITY(U,$J,358.3,33147,2)
 ;;=^5007789
 ;;^UTILITY(U,$J,358.3,33148,0)
 ;;=I73.9^^131^1667^19
 ;;^UTILITY(U,$J,358.3,33148,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33148,1,3,0)
 ;;=3^Peripheral Vascular Disease,Unspec
 ;;^UTILITY(U,$J,358.3,33148,1,4,0)
 ;;=4^I73.9
 ;;^UTILITY(U,$J,358.3,33148,2)
 ;;=^184182
 ;;^UTILITY(U,$J,358.3,33149,0)
 ;;=I82.891^^131^1667^14
 ;;^UTILITY(U,$J,358.3,33149,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33149,1,3,0)
 ;;=3^Embolism/Thrombosis Oth Spec Veins,Chronic
 ;;^UTILITY(U,$J,358.3,33149,1,4,0)
 ;;=4^I82.891
 ;;^UTILITY(U,$J,358.3,33149,2)
 ;;=^5007939
 ;;^UTILITY(U,$J,358.3,33150,0)
 ;;=I82.890^^131^1667^13
 ;;^UTILITY(U,$J,358.3,33150,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33150,1,3,0)
 ;;=3^Embolism/Thrombosis Oth Spec Veins,Acute
 ;;^UTILITY(U,$J,358.3,33150,1,4,0)
 ;;=4^I82.890
 ;;^UTILITY(U,$J,358.3,33150,2)
 ;;=^5007938
 ;;^UTILITY(U,$J,358.3,33151,0)
 ;;=E78.0^^131^1668^12
 ;;^UTILITY(U,$J,358.3,33151,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33151,1,3,0)
 ;;=3^Pure Hypercholesterolemia
 ;;^UTILITY(U,$J,358.3,33151,1,4,0)
 ;;=4^E78.0
 ;;^UTILITY(U,$J,358.3,33151,2)
 ;;=^5002966
 ;;^UTILITY(U,$J,358.3,33152,0)
 ;;=E78.1^^131^1668^13
 ;;^UTILITY(U,$J,358.3,33152,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33152,1,3,0)
 ;;=3^Pure Hyperglyceridemia
 ;;^UTILITY(U,$J,358.3,33152,1,4,0)
 ;;=4^E78.1
 ;;^UTILITY(U,$J,358.3,33152,2)
 ;;=^101303
 ;;^UTILITY(U,$J,358.3,33153,0)
 ;;=E78.2^^131^1668^11
 ;;^UTILITY(U,$J,358.3,33153,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33153,1,3,0)
 ;;=3^Mixed Hyperlipidemia
 ;;^UTILITY(U,$J,358.3,33153,1,4,0)
 ;;=4^E78.2
 ;;^UTILITY(U,$J,358.3,33153,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,33154,0)
 ;;=I10.^^131^1668^3
 ;;^UTILITY(U,$J,358.3,33154,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33154,1,3,0)
 ;;=3^Essential Primary Hypertension
 ;;^UTILITY(U,$J,358.3,33154,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,33154,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,33155,0)
 ;;=I11.9^^131^1668^10
 ;;^UTILITY(U,$J,358.3,33155,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33155,1,3,0)
 ;;=3^Hypertensive Heart Disease w/o Heart Failure
 ;;^UTILITY(U,$J,358.3,33155,1,4,0)
 ;;=4^I11.9
 ;;^UTILITY(U,$J,358.3,33155,2)
 ;;=^5007064
 ;;^UTILITY(U,$J,358.3,33156,0)
 ;;=I11.0^^131^1668^9
 ;;^UTILITY(U,$J,358.3,33156,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33156,1,3,0)
 ;;=3^Hypertensive Heart Disease w/ Heart Failure
 ;;^UTILITY(U,$J,358.3,33156,1,4,0)
 ;;=4^I11.0
 ;;^UTILITY(U,$J,358.3,33156,2)
 ;;=^5007063
 ;;^UTILITY(U,$J,358.3,33157,0)
 ;;=I12.0^^131^1668^8
 ;;^UTILITY(U,$J,358.3,33157,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33157,1,3,0)
 ;;=3^Hypertensive Chr Kidney Disease w/ ESRD
 ;;^UTILITY(U,$J,358.3,33157,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,33157,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,33158,0)
 ;;=I13.10^^131^1668^6
 ;;^UTILITY(U,$J,358.3,33158,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33158,1,3,0)
 ;;=3^HTN Hrt & Chr Kdny Dis w/o Hrt Fail w/ Stg 1-4 Chr Kdny
 ;;^UTILITY(U,$J,358.3,33158,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,33158,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,33159,0)
 ;;=I13.0^^131^1668^4
 ;;^UTILITY(U,$J,358.3,33159,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33159,1,3,0)
 ;;=3^HTN Hrt & Chr Kdny Dis w/ Hrt Fail w/ Stg 1-4 Chr Kdny
 ;;^UTILITY(U,$J,358.3,33159,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,33159,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,33160,0)
 ;;=I13.11^^131^1668^7
 ;;^UTILITY(U,$J,358.3,33160,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33160,1,3,0)
 ;;=3^HTN Hrt & Chr Kdny Dis w/o Hrt Fail w/ Stg 5 Chr Kdny
